Targovax ASA announced the appointment of Victor Levitsky as Chief Scientific Officer. He will play a leading role in driving research strategy and pipeline expansions, particularly the scientific and mechanistic aspects of early clinical work. Dr Levitsky will serve as a member of Targovax's management team. Dr. Levitsky is a seasoned internationally recognized expert in immunology, oncology, T-cell immunotherapy and immuno-oncology with in-depth knowledge of preclinical, translational and early stage clinical drug development. He brings extensive experience in pre-clinical drug development of protein-based biologics and small molecules.